News

Industry acknowledgements

We provide breakthrough approaches with our patented IP in sRNA research

Isomicro-RNAs’ levels in blood as measured by assay
FDA Letter of Support
Salzman DW

View

Biomarkers for the early-detection and monitoring of Huntington’s disease
7th World CNS Summit: Targeting Neurodegenerative Diseases, Boston, MA (2019)
Salzman DW, Bregu J, Ray NS, Myers RH

View

Biomarkers for the early-detection and monitoring of Huntington’s Disease
RNA-Based Biomarker Grant (completion 2021)
Salzman DW, Bregu J, Ray NS, Myers RH

View

An AI-driven platform to classify and subtype CNS disease using small RNAs
Neuroimaging and CSF Biomarker Development Grant (completion 2021)
Salzman DW, Melconian T, Foster N, Ray NS

View

Gatehouse in the news

Business Wire: December 2019

Business Wire: February 2019

Pharma Tech Outlook

Biospace: December 2017

Biospace: August 2017

Next: Contact us to take the next step

Contact Us

Thanks for your interest! Please fill out the form below to download a copy of our case study

David Salzman, PhD

As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.


View his publication record here.

If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.